Brand GLP-1s buy you the FDA-approved product itself — the exact pens the trials tested, manufacturer QC, an outcome-bearing label — at list prices around $1,000–1,350/month before programs (manufacturer lists; verify current). Personalized compounded versions from state-licensed pharmacies are lawful in defined lanes and anchor the verified cash floor here: $119–169/month, dated. The decision is a risk/cost/eligibility triangle, not a moral one.
What each word actually means
Brand-name: Wegovy, Ozempic, Zepbound, Mounjaro — FDA-approved drug products with manufacturer-controlled production, device-metered dosing, and labels earned by the outcome trials. Compounded: the same active molecules prepared by state-licensed 503A/503B pharmacies for individual prescriptions — a lawful, regulated practice that is not FDA approval of the finished vial. Neither describes gray-market “research peptides,” which are a different, dangerous category.
Legality in 2026, plainly
The shortage-era mass-copying window closed with the delistings; what remains legal is personalized compounding under state pharmacy law — clinician-specific prescriptions, licensed pharmacies, patient-specific rationale. Reported March-2026 FDA warning letters to non-compliant telehealth sellers (verify current) targeted the operators ignoring exactly those requirements. Full analysis: the legal-status file.
The cost math, honestly
Verified compounded floor on our ledger: semaglutide $119–139, tirzepatide $139–169 monthly by term — $1,428–1,668/year, flat at every dose, $0 fees (2026-08-20). Brand list runs roughly $12,000–16,000/year before the lanes that matter: insurance with prior authorization (playbook), manufacturer self-pay programs (NovoCare, LillyDirect — figures move; verify), savings cards for the covered, and the Medicare Bridge for eligible beneficiaries. A covered patient with a $25 copay should almost never pay cash for compounded; an uncovered cash payer runs the arithmetic the other way.
The risk axis — what brand buys, what verification replaces
Brand buys certainty: every pen identical, dosing metered by device, stability data on the label, the trial evidence generated on that product. Compounded shifts quality assurance onto pharmacy selection — which is why the verification checklist exists: state Board of Pharmacy licensure you look up yourself, 503B registration where applicable, beyond-use dating, willingness to show testing documentation. A verified pharmacy narrows the gap; an unverifiable one is the gray market with better typography.
The decision, axis by axis
| Axis | Brand-name | Compounded (verified pharmacy) |
|---|---|---|
| FDA approval | The finished product itself | The molecule’s pharmacology; not the finished vial |
| Verified cash cost | ≈$1,000–1,350/mo list before programs (mfr lists; verify) | $119–169/mo flat, dated 2026-08-20 |
| Dosing hardware | Device-metered pens | Vial + syringe; technique matters |
| Outcome-trial labels | Yes — CV, OSA, kidney indications where earned | No indication labels; same molecule, no label claims |
| Insurance route | Yes, with prior authorization | Almost never covered |
| Quality assurance | Manufacturer QC, lot-tracked | Your verification: licensure, 503 status, testing docs |
| Dose flexibility | Fixed pen steps | Titration-friendly, microdose-capable |
The middle lanes most people miss
The brand-vs-compounded frame hides three hybrid routes that often beat both defaults. Savings cards can pull a covered brand prescription to double-digit copays — always price this first if any coverage exists. Manufacturer self-pay (LillyDirect vials, NovoCare pharmacy) puts real brand product below list for cash payers — figures move; verify on the manufacturers’ pages. And the Medicare Bridge (per CMS, launched July 2026 — verify) reroutes eligible beneficiaries to ~$50/month brand access no compounded price can answer. Run all three before treating the binary as real.
Red flags in either direction
Toward compounded: a pharmacy the telehealth brand won’t name, no state-license lookup hit, “research use” language, or prices so far under the verified floor that testing and licensure can’t be in the budget — that’s the gray market in costume. Toward brand: paying $1,000+ cash without ever running a prior authorization, a savings-card check, or a manufacturer-program quote — the most expensive form of not asking. Either way, the fix is the same: verify, in writing, before your card moves.
Who should lean which way
Lean brand: coverage in hand or winnable on appeal; OSA or cardiovascular indications in play; device preference; anyone uncomfortable with pharmacy-level diligence. Lean compounded (verified): uncovered cash payers for whom $119–169 vs $1,000+ is the whole ballgame; microdose/maintenance protocols brand pens don’t map to. Switching between them is routine and molecule-preserving — the switching file walks the dose-mapping, device, and timing details.
Related rosters: the 18-provider ranking · cheapest overall · compounded vs brand · every fee field, dated.
Common questions
Is compounded semaglutide legal?
In the defined lane, yes: personalized prescriptions filled by state-licensed 503A/503B pharmacies. What ended in the post-shortage era is mass copying; what continues is regulated, patient-specific compounding. Verify the pharmacy’s license yourself — our checklist shows where.
Is compounded tirzepatide still available?
Yes, via the same licensed personalization lane, with reported 2026 enforcement (verify current) pruning non-compliant sellers rather than the practice itself. Availability is pharmacy-by-pharmacy; legitimacy is checkable in minutes.
How do I verify a compounding pharmacy?
Three checks: (1) look up the pharmacy — not just the telehealth brand — on its state Board of Pharmacy license database; (2) confirm 503A patient-specific status or 503B FDA registration; (3) ask for testing/COA documentation and a straight answer on beyond-use dating. Refusal on any of the three is your answer.
When is brand clearly worth the premium?
When insurance or a manufacturer program collapses the price gap; when an outcome indication (cardiovascular, OSA, kidney) is part of your clinical picture, since those labels belong to the branded products the trials tested; and when device-metered dosing meaningfully de-risks your routine.
Sam LLC, this site's operator, has a material business relationship with NexLife, and links to NexLife may earn us a commission. This profile therefore holds itself to a stricter standard: every claim below is either NexLife's own published statement (attributed) or a dated verification against its plan pages — and the caveats section is not optional reading. Full disclosure · methodology.